CD274 and small cell lung carcinoma: The KEYNOTE-028 study demonstrated promising antitumor activity in patients with PD-L1-expressing SCLC (ORR, 33%; 95% CI, 16%-55%).[20] CPI plus chemotherapy is expected to be an important strategy for improving the efficacy of immune therapy.[21,22] Furthermore, nab-PTX does not require co-administration of a glucocorticoid, which has the potential to attenuate immune responses and, therefore, may be beneficial for use as a chemotherapy with CPIs.